OX40-enhanced tumor rejection and effector T cell differentiation decreases with age

Journal of Immunology

Volumn 182, Issue 3, 2009, Pages 1481-1489

  Ruby, Carl E ^a   Weinberg, Andrew D ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; INTERLEUKIN 2; ANTIBODY; AUTACOID; INTERLEUKIN 12; TNFRSF4 PROTEIN, MOUSE;

ADOLESCENT; AGED; ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; AGING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; COLON TUMOR; COMPARATIVE STUDY; DRUG ANTAGONISM; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SARCOMA; TRANSGENIC MOUSE; TUMOR CELL LINE;

AGING; ANIMALS; ANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GRAFT REJECTION; INFLAMMATION MEDIATORS; INTERLEUKIN-12; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, OX40; SARCOMA, EXPERIMENTAL;

EID: 63149184826     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.3.1481     Document Type: Article

References (51)

1. Ershler, W. B. 1993. The influence of an aging immune system on cancer incidence and progression. J. Gerontol. 48: B3-B7.
2. Yung, R. L. 2000. Changes in immune function with age. Rheum. Dis. Clin. North Am. 26: 455-473.
3. Linton, P. J., L. Haynes, L. Tsui, X. Zhang, and S. Swain. 1997. From naive to effector: alterations with aging. Immunol. Rev. 160: 9-18.
4. Effros, R. B., and R. L. Walford. 1983. The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol. 81: 298-305.
5. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3: 682-685.
6. Ye, Z., I. Hellstrom, M. Hayden-Ledbetter, A. Dahlin, J. A. Ledbetter, and K. E. Hellstrom. 2002. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8: 343-348.
7. Bansal-Pakala, P., and M. Croft. 2002. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J. Immunol. 169: 5005-5009.
8. Kjaergaard, J., L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu. 2001. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167: 6669-6677.
9. Weinberg, A. D., M. M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164: 2160-2169.
10. Maxwell, J. R., A. Weinberg, R. A. Prell, and A. T. Vella. 2000. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164: 107-112.
11. Evans, D. E., M. W. Munks, J. M. Purkerson, and D. C. Parker. 2000. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/ CD40. J. Immunol. 164: 688-697.
12. Imura, A., T. Hori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura, and T. Uchiyama. 1996. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183: 2185-2195.
13. + T cells. Int. Immunol. 10: 453-461.
14. + memory T cell survival and significantly increases recall responses. Eur. J. Immunol. 37: 157-166.
15. Lustgarten, J., A. L. Dominguez, and M. Thoman. 2004. Aged mice develop protective antitumor immune responses with appropriate costimulation. J. Immunol. 173: 4510-4515.
16. Kopf, M., C. Ruedl, N. Schmitz, A. Gallimore, K. Lefrang, B. Ecabert, B. Odermatt, and M. F. Bachmann. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 11: 699-708.
17. Kjaergaard, J., J. Tanaka, J. A. Kim, K. Rothchild, A. Weinberg, and S. Shu. 2000. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60: 5514-5521.
18. + T cell mobilization/ memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J. Immunol. 167: 6804-6811.
19. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
20. Watford, W. T., M. Moriguchi, A. Morinobu, and J. J. O'Shea. 2003. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 14: 361-368.
21. Kretschmer, K., I. Apostolou, E. Jaeckel, K. Khazaie, and H. von Boehmer. 2006. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol. Rev. 212: 163-169.
22. Vignali, D. A., L. W. Collison, and C. J. Workman. 2008. How regulatory T cells work. Nat. Rev. Immunol. 8: 523-532.
23. Ruby, C. E., R. Montler, R. Zheng, S. Shu, and A. D. Weinberg. 2008. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J. Immunol. 180: 2140-2148.
24. Kuriyama, H., S. Watanabe, J. Kjaergaard, H. Tamai, R. Zheng, A. D. Weinberg, H. M. Hu, P. A. Cohen, G. E. Plautz, and S. Shu. 2006. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol. 243: 30-40.
25. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
26. Pages, F., A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, et al. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353: 2654-2666.
27. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348: 203-213.
28. Gough, M. J., C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg. 2008. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68: 5206-5215.
29. Song, A., X. Tang, K. M. Harms, and M. Croft. 2005. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J. Immunol. 175: 3534-3541.
30. Song, A., J. Song, X. Tang, and M. Croft. 2007. Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur. J. Immunol. 37: 1224-1232.
31. Mittler, J. N., and W. T. Lee. 2004. Antigen-specific CD4 T cell clonal expansion and differentiation in the aged lymphoid microenvironment, I: the primary T cell response is unaffected. Mech. Ageing Dev. 125: 47-57.
32. Haynes, L., S. M. Eaton, E. M. Burns, T. D. Randall, and S. L. Swain. 2005. Newly generated CD4 T cells in aged animals do not exhibit age-related defects in response to antigen. J. Exp. Med. 201: 845-851.
33. Eaton, S. M., E. M. Burns, K. Kusser, T. D. Randall, and L. Haynes. 2004. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J. Exp. Med. 200: 1613-1622.
34. + recent thymic emigrants from aged mice. J. Immunol. 178: 1321-1331.
35. Li, S. P., Z. Cai, W. Shi, A. Brunmark, M. Jackson, and P. J. Linton. 2002. Early antigen-specific response by naive CD8 T cells is not altered with aging. J. Immunol. 168: 6120-6127.
36. Linton, P. J., S. P. Li, Y. Zhang, B. Bautista, Q. Huynh, and T. Trinh. 2005. Intrinsic versus environmental influences on T-cell responses in aging. Immunol. Rev. 205: 207-219.
37. Haynes, L., S. M. Eaton, E. M. Burns, M. Rincon, and S. L. Swain. 2004. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J. Immunol. 172: 5194-5199.
38. Win, S., A. Uenaka, and E. Nakayama. 2002. Immune responses against allogeneic and syngeneic tumors in aged C57BL/6 mice. Microbiol. Immunol. 46: 513-519.
39. Sharma, S., A. L. Dominguez, and J. Lustgarten. 2006. Aging affect the antitumor potential of dendritic cell vaccination, but it can be overcome by costimulation with anti-OX40 or anti-4-1BB. Exp. Gerontol. 41: 78-84.
40. Curiel, T. J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117: 1167-1174.
41. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
42. Ormandy, L. A., T. Hillemann, H. Wedemeyer, M. P. Manns, T. F. Greten, and F. Korangy. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65: 2457-2464.
43. + T regulatory cells: role of tumor-derived TGF-β. J. Immunol. 178: 2883-2892.
44. + T cells. J. Immunol. 179: 1427-1430.
45. + Tregs. Blood 110: 2501-2510.
46. Piconese, S., B. Valzasina, and M. P. Colombo. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205: 825-839.
47. + regulatory T cells in part by expanding memory T cells in vivo. J. Immunol. 181: 3193-3201.
48. + regulatory T cells. Proc. Natl. Acad. Sci. USA 104: 18169-18174.
49. Connoy, A. C., M. Trader, and K. P. High. 2006. Age-related changes in cell surface and senescence markers in the spleen of DBA/2 mice: a flow cytometric analysis. Exp. Gerontol. 41: 225-229.
50. Mo, R., J. Chen, Y. Han, C. Bueno-Cannizares, D. E. Misek, P. A. Lescure, S. Hanash, and R. L. Yung. 2003. T cell chemokine receptor expression in aging. J. Immunol. 170: 895-904.
51. Macieira-Coelho, A. 2001. Neoplastic disease through the human life span. Biogerontology 2: 179-192.